NCT06562907View on ClinicalTrials.gov

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

PHASE1RecruitingINTERVENTIONAL

Enrollment

134

Participants

Timeline

Start Date

August 28, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Weight Management

Interventions

DRUG

GS-4571

Administered orally

DRUG

Placebo

Administered orally

DRUG

Omeprazole

Administered orally

Trial Locations (2)

78209

RECRUITING

ICON Early Phase Services, LLC, San Antonio

84124

RECRUITING

ICON, Salt Lake City

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY